Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash from Operations (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Cash from Operations for 5 consecutive years, with 43485000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 203.53% to 43485000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 170866000.0 through Dec 2025, down 1361.19% year-over-year, with the annual reading at 170866000.0 for FY2025, 1361.19% down from the prior year.
  • Cash from Operations hit 43485000.0 in Q4 2025 for ARS Pharmaceuticals, up from 47047000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 42004000.0 in Q4 2024 to a low of 47047000.0 in Q3 2025.
  • Historically, Cash from Operations has averaged 13711150.0 across 5 years, with a median of 13449000.0 in 2021.
  • Biggest five-year swings in Cash from Operations: surged 341.33% in 2024 and later crashed 507.18% in 2025.
  • Year by year, Cash from Operations stood at 27894000.0 in 2021, then crashed by 173.48% to 20497000.0 in 2022, then rose by 15.09% to 17405000.0 in 2023, then soared by 341.33% to 42004000.0 in 2024, then tumbled by 203.53% to 43485000.0 in 2025.
  • Business Quant data shows Cash from Operations for SPRY at 43485000.0 in Q4 2025, 47047000.0 in Q3 2025, and 39592000.0 in Q2 2025.